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Abstract 
A collision tumor of the stomach is a rare event. We report the case of a collision tumor 
of the stomach consisting of an adenocarcinoma and a gastrointestinal stromal tumor 
(GIST). This is, to our knowledge, the second report in the literature of such a case. A 71-
year-old man with abdominal discomfort underwent an esophagogastroduodenoscopy 
which revealed a tumor of the oesophagogastric junction. A total gastrectomy was 
performed. Histologic examination showed a mixed tumor consisting of a primary 
adenocarcinoma and multiple nodules of GIST. The adenocarcinoma showed both diffuse 
and intestinal growth, angio-invasion and metastasis to lymph nodes. The GIST tumor 
cells were strongly immunoreactive to CD117 and CD34. Based on mitotic index, size and 
cytonuclear details, the biological behavior of this GIST tumor was supposed to be 
benign. This case reports the rare finding of a collision tumor consisting of an 
adenocarcinoma and a GIST with an unknown etiology. 
 
Introduction 
Adenocarcinoma is the most common malignant gastric tumor, while gastrointestinal 
stromal tumors (GISTs) are relatively rare [1]. From all gastrointestinal locations, GISTs 
occur most frequently in the stomach (60–70%) [1]. However, a combination of an 
adenocarcinoma and a GIST is a very rare finding and an actual collision of these tumors 
even more so. This case report is, to our best knowledge, the second report in literature.  
Case Rep Gastroenterol 2008;2:456–460 
DOI: 10.1159/000129707 








A 71-year-old man presented with vague abdominal discomfort. Physical examination was 
unremarkable. Laboratory data demonstrated an ESR of 15 mm/h (normal 1–7 mm/h), a hemoglobin 
level of 6.5 mmol/l (normal 8.5–11.0 mmol/l), thrombocytes 341 × 10
9 (normal 150–400 × 10
9), 
leukocytes 8.9 × 10
9 (normal 4.0–10.0 × 10
9). Renal and liver function tests were normal. 
Esophagogastroduodenoscopy revealed a tumor at the oesophagogastric junction from which biopsies 
were taken. Histologic examination revealed an adenocarcinoma. 
Chest X-ray did not show any signs of metastasis. Endosonography showed an irregular course of 
the gastric wall where it was adjacent to the liver, not excluding possible invasive growth into the liver 
and thus suggesting the possibility of a T4 carcinoma. Sonography of the neck region and the abdomen 
showed no lymph node involvement or signs of metastasis to other organs. Primary surgery consisting 
of a total gastrectomy with Roux-en-Y esophagojejunostomy was performed. Except from a 
postoperative septic period as a result of a spondylodiscitis, which was successfully treated with 
antibiotics, the patient was postoperatively discharged in clinically good condition after six weeks. Two 
and a half years after the total gastrectomy the patient developed pleural effusion due to 
adenocarcinoma metastases and died shortly thereafter. 
Pathologic Findings 
The resected specimen consisted of a totally resected stomach with en bloc part of the distal 
oesophagus. Alongside the lesser curvature there was a tumor, measuring 5 × 4 × 2.5 cm. On cut section 
the tumor invaded through the muscularis propria into the fat of the omentum minus. Microscopically 
the tumor consisted of both a conventional adenocarcinoma and tumor nodules composed of cells with 
another phenotype. Most of the adenocarcinoma was found in the submucosa, but focally the 
adenocarcinoma invaded all layers of the gastric wall into the outer serosal surface or perigastric fat. 
This tumor was composed of a combination of intestinal, gland-forming growth and a diffuse, poorly 
adhesive, often signet-ring morphology. There was also angioinvasive growth. The proximal and distal 
resection margins were free of tumor. Metastasis was found in 5 of the 8 resected lymph nodes. 
The other tumor was found multifocal in the submucosa, muscularis propria and subserosa. It 
consisted of nodules up to 6 mm composed of spindle cells with little cytonuclear polymorphism and 
with no significant amount of mitosis (<5/50 HPF) (fig. 1a). These cells expressed high levels of CD117 
(fig. 1b) and CD34, while other stromal cell markers like S100, smooth muscle actin and desmin were 
not expressed. It was therefore concluded that these tumor nodules were GIST. Figure 1c shows the 
actual ‘collision’ between the adenocarcinoma and the GIST. 
Discussion 
GISTs were first mentioned in 1983 by Mazur and Clark [2]. These tumors are the 
most common mesenchymal tumors in the digestive tract and are thought to originate 
either from the stem cells that differentiate towards interstitial cells of Cajal, or directly 
from interstitial cells of Cajal [3, 4]. Small GISTs are often detected incidentally during 
surgery for other reasons, or are detected during gastroscopy [1]. In general, GISTs can be 
differentiated from other tumors made up from spindle cells and/or epitheloid cells by 
expressing CD117 (c-kit) and CD34 in 50–80% of cases [3, 4]. The KIT gene codes for c-
kit protein which activates a tyrosine kinase after binding with a stem cell factor. 90% of 
GISTs have a mutation in the KIT oncogene, but 10% miss this mutation [4]. These 
sometimes CD117-negative tumors often have a mutation in the platelet-derived growth 
factor receptor α (PDGFRα). 
Nowadays, the prognosis and biological behaviour of GIST depends on a combination 
of two criteria: the size of the tumor and the mitotic index [1]. Surgical resection is the  
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primary treatment for GIST. Approximately 70–85% of patients have a complete 
resection, but overall five-year survival is only 50%, because of the tendency of the GIST 
to metastasize or to recur. Since 2002 a new therapy, imatinib mesylate, is developed to 
treat this kind of malignancies when metastasized or irresectable. This is a tyrosine kinase 
inhibitor and demonstrates dramatic effects in the majority of patients. 80% of patients 
have either a response or stable disease with imatinib treatment [5]. 
After several years of treating patients with imatinib, resistance has developed. 
Approximately 50% of patients do not respond after two years of treatment [6]. Possibly 
the kind of KIT gene mutation has an effect on the development of resistance and the 
tumor response on imatinib [4]. 
Collision tumors are defined as morphologically different neighboring neoplasms that 
do not intermingle [7]. The development of gastric collision tumors is very rare. In the 
English literature we found one case report describing the occurrence of an 
adenocarcinoma mixed with a GIST [8]. Several cases describing various other 
combinations of tumor have been reported [7, 9–11]. Various hypotheses have been 
proposed about synchronous occurrence of GIST and adenocarcinoma. They considered 
whether or not such an association was incidental or whether the two lesions were 
connected by a causal relationship. Some articles suggest that gene mutations or a single 
carcinogenic agent might interact with two neighboring tissues, inducing the 
development of tumors of different histiotypes in the same organ, but no evidence of this 
last hypothesis has yet been found [8, 10]. Both tumors have different precursor cells and 
molecular make-up, and if there were a single carcinogen, these types of tumor would 
probably be diagnosed more often. 
In this case the diagnosis of GIST was made based on the tumor phenotype in 
combination with immunoreactivity to CD117 and CD34. The GIST was presumed to be 
benign due to the low mitotic count, size and to a lesser extent the low degree of 
cellularity and cellular polymorphism. Although multicentricity is often considered a sign 
of malignancy, in this case, only very small nodules with no histological signs of 
malignant clinical behavior were present. Therefore it was expected that in this case the 
prognosis would most probably be determined by the adenocarcinoma component as this 
tumor penetrated the entire gastric wall into the serosa, had invaded blood vessels and 
showed lymph node metastasis. 
Conclusion 
We present a patient suffering from a collision tumor consisting of an adenocarcinoma 
originating from the gastric mucosa and a GIST that was presumed to behave in a benign 
fashion. As shown by the adenocarcinoma metastasis in the pleural effusion and death 
two and a half years after surgery, the patient’s prognosis was determined by the 
adenocarcinoma component. Two primary tumors of the stomach are a rare event. 
However, an actual collision of both an epithelial adenocarcinoma and a GIST is 
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Fig. 1. a Gastric wall: hematoxylin and eosin. Tumor nodule in relation to the muscularis propria. The 
tumor cells are composed of spindle cells and partly storiform, show moderate cytonuclear 
polymorphism without obvious mitoses or necrosis. M = Mucosa; T = tumor; MP = muscularis 
propria. b Gastric wall: immonuhistochemistry. Gastrointestinal stromal tumor showing CD117 
expression. Insert: Detail of tumor cells with the aspects described in figure 1. M = Mucosa; T = tumor; 
MP = muscularis propria. c Gastric wall: hematoxylin and eosin. Collision of the infiltrating 
adenocarcinoma originated from the gastric mucosa and the GIST. A = Adenocarcinoma; G = GIST;  
C = calcification. 
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